To analysis the clinical characteristics and prognosis of multiple myeloma patients resisting to VRD(Bortezomib,Lenalidomide,Dexamethasone)
10.3781/j.issn.1000-7431.2023.2303-0134
- VernacularTitle:VRD耐药多发性骨髓瘤患者的临床特征及预后分析
- Author:
Jing JIA
1
;
Wenming CHEN
;
Chuanying GENG
;
Guangzhong YANG
;
Huixing ZHOU
;
Yuan JIAN
;
Nian LIU
;
Zhiyao ZHANG
Author Information
1. 首都医科大学附属北京朝阳医院血液科,北京 100020
- Keywords:
Multiple myeloma;
Bortezomib;
Lenalidomide;
Dexamethasone;
Refractory
- From:
Tumor
2023;43(9):701-709
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical features and prognosis of multiple myeloma(MM)patients who resisted to the combination of bortezomib,lenalidomide and dexamethasone(VRD). Methods:The clinical features and prognosis of 150 patients with newly diagnosed MM in Beijing Chaoyang Hospital who were treated with VRD from January 2015 to January 2020 were retrospectively analyzed by SPSS software. Results:Among a total of 150 MM patients,21 patients resisted to VRD,including 14 patients with primary refractory to VRD and 7 patients with early relapse.In the VRD-resistant group(n=21),the median age of patients was 58 years(37-70 years),and female patients were more common(61.9％);Durie-Salmon stage:17 patients were DS stage Ⅲ,4 patients were DS stage Ⅱ;44.4％of those patients were cytogenetic high risk.CD20 positive rate was higher in the VRD-resistant group(P=0.014).The overall survival(OS)of MM patients in the VRD-resistant group was significantly lower than that in the VRD-nonresistant group(34 months vs not achieved,P＜0.001).In the VRD-resistant group,the median OS of MM patients receiving autologous hematopoietic stem cell transplantation was significantly longer than that of non-transplant patients(34 months vs 16 months,P=0.038).Drug resistance and non-autologous transplantation are independent adverse prognostic factors for newly diagnosed MM patients receiving VRD induction chemotherapy.COX multivariate analysis showed that age＞65,cytogenetic high risk and non-autologous stem cell transplantation may be adverse prognostic factors for VRD-resistant MM patients. Conclusion:Positive CD20 was more common in MM patients with VRD resistence,which may indicate more aggressive biological characteristics in VRD-resistent MM patients.The VRD-resistent MM patients had poor prognosis,they can obtain disease remission from salvage chemotherapy including daratumumab,and the survival of them also can be improved after autologous stem cell transplantation.
